Filing Flows

Filing Flows › Lipocine (LPCN) › Next earnings date

Lipocine (LPCN) earnings: beat the estimate

Lipocine (LPCN) reported on Nov 5, 2026 and beat the EPS estimate: −$0.08 against −$0.35 (+77.5%). Revenue was $2.3M for Q3 2026, 20× year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+77.5% vs estimate
Beat rate60%

The last report

Lipocine reported revenue of $2.3M for the third quarter 2026 (20× Y/Y), net loss $666K. How it makes money → · Every quarter →

Lipocine: EPS against the estimate, last 5 reportsLipocine: EPS against the estimate, last 5 reportsEstimateReported−$0.54−$0.59Nov 25−$0.61−$0.42Mar 26−$0.48−$0.54May 26−$0.40−$0.32Aug 26−$0.35−$0.08Nov 26
Latest (Nov 26): Estimate −$0.35, Reported −$0.08.

Lipocine's latest quarter

Lipocine, Q3 2026: revenue $2.3M (20× year over year), operating margin -37.9%, net loss $666K, operating cash flow −$1.8M. The chart follows the revenue to costs, profit and cash.

Questions

Did Lipocine beat earnings?

Lipocine (LPCN) reported on Nov 5, 2026 and beat the EPS estimate: −$0.08 against −$0.35 (+77.5%).

When does LPCN report earnings?

The next date is not set yet.

Does Lipocine usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.